Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLC

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the importance of initial therapy selection in ALK-positive non­—small cell lung cancer (NSCLC).

Patients will eventually develop resistance to ALK inhibitors, says Saxena. Secondary mutations may develop as a result of insufficient suppression of ALK or bypass pathways.

Specific secondary mutations that may arise following treatment with crizotinib (Xalkori) or alectinib (Alecensa) are sensitive to next-generation agents such as brigatinib (Alunbrig) and lorlatinib (Lorbrena).

As such, optimizing first-line treatment selection is necessary as it may influence which agents are available to the patient upon disease progression, concludes Saxena.

Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
© 2023 MJH Life Sciences

All rights reserved.